Working... Menu

Study of Pembrolizumab Following TACE in Primary Liver Carcinoma (PETAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03397654
Recruitment Status : Recruiting
First Posted : January 12, 2018
Last Update Posted : June 10, 2019
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Imperial College London

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : March 31, 2020
  Estimated Study Completion Date : December 31, 2020